Menu
Back to Journals » Drug Design, Development and Therapy » Volume 9
Design, synthesis, and antitumor evaluation of histone deacetylase inhibitors with L-phenylglycine scaffold
Authors Zhang Y, Li X, Hou J, Huang Y, Xu W
Received 8 August 2015
Accepted for publication 9 September 2015
Published 8 October 2015 Volume 2015:9 Pages 5553—5567
DOI https://doi.org/10.2147/DDDT.S94037
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Wei Duan
Yingjie Zhang,1 Xiaoguang Li,1 Jinning Hou,1 Yongxue Huang,2 Wenfang Xu1
1Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Ji’nan, 2Weifang Bochuang International Biological Medicinal Institute, Weifang, Shandong, People’s Republic of China
Abstract: In our previous research, a novel series of histone deacetylase (HDAC) inhibitors with L-phenylglycine scaffold were designed and synthesized, among which amides D3 and D7 and ureido D18 were far superior to the positive control (suberoylanilide hydroxamic acid [SAHA]) in HDAC inhibition, but were only comparable to SAHA in antiproliferation on tumor cell lines. Herein, further structural derivation of lead compounds D3, D7, and D18 was carried out to improve their cellular activities. Most of our newly synthesized compounds exhibited more potent HDAC inhibitory activities than the positive control SAHA, and several derivatives were even better than their parent compounds. However, compared with SAHA and our lead compounds, only secondary amine series compounds exhibited improved antiproliferative activities, likely due to their appropriate topological polar surface area values and cell permeabilities. In a human histiocytic lymphoma (U937) xenograft model, the most potent secondary amine 9d exhibited similar in vivo antitumor activity to that of SAHA.
Keywords: phenylglycine, histone deacetylases, inhibitor, antitumor
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.